Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field

Correlates of protection (CoPs) can play a significant role in vaccine development by assisting the selection of vaccine candidates for clinical trials, supporting clinical trial design and implementation, and simplifying tests of vaccine modifications. Because of this important role in vaccine deve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Viral immunology Jg. 31; H. 2; S. 195 - 203
Hauptverfasser: Kulkarni, Prasad S., Hurwitz, Julia L., Simões, Eric A.F., Piedra, Pedro A.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Los Angeles, CA Mary Ann Liebert, Inc 01.03.2018
SAGE Publications
Schlagworte:
Children & youth
Clinical trials
Considerations for Future Vaccine Development
Cytokines
Hospitals
Immune response (humoral)
Immunogenicity
Immunoglobulins
Infants
Infections
Infectious diseases
Influenza
Lymphocytes
Medical research
Monoclonal antibodies
Pediatrics
Product development
Rabies
Regulatory agencies
Researchers
Respiratory syncytial virus
Vaccine development
Vaccines
United States > US
Colorado
Tennessee
India
vaccine efficacy
neutralizing antibody
ISSN:0882-8245, 1557-8976, 1557-8976
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Correlates of protection (CoPs) can play a significant role in vaccine development by assisting the selection of vaccine candidates for clinical trials, supporting clinical trial design and implementation, and simplifying tests of vaccine modifications. Because of this important role in vaccine development, it is essential that CoPs be defined by well-designed immunogenicity and efficacy studies, with attention paid to benefits and limitations. The respiratory syncytial virus (RSV) field is unique in that a great deal of information about the humoral response is available from basic research and clinical studies. Polyclonal and monoclonal antibodies have been used routinely in the clinic to protect vulnerable infants from infection, providing a wealth of information about correlations between neutralizing antibodies and disease prevention. Considerations for the establishment of future CoPs to support RSV vaccine development in different populations are therefore discussed.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:0882-8245
1557-8976
1557-8976
DOI:10.1089/vim.2017.0147